Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Bioorg Med Chem Lett. 2011 Jun 28;21(18):5528–5532. doi: 10.1016/j.bmcl.2011.06.099

Figure 3.

Figure 3

Luciferase reporter assays showing the effect of arylsulfonamide HIF pathway inhibitors on the activity of a VEGF promoter-luciferase construct, stably transfected in LN229 glioma cells (LN229-VEGF-luc). Cells were pre-treated with inhibitors (10 μM final concentration) for 1 h in normoxia, followed by 24 hrs incubation in normoxia or hypoxia and luciferase measured in cell extracts as indicated in Fig. 2. Each value represents an average from triplicates +/− standard deviation.